{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon+Alfa&page=2", "query": { "intervention": "Interferon Alfa", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon+Alfa&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T18:50:34.631Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003007", "title": "Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of Tennessee", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "19 Years to 64 Years" }, "enrollment_count": null, "start_date": "1996-07", "completion_date": "2004-01", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-09-26T18:50:34.631Z", "location_count": 4, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003007" }, { "nct_id": "NCT04726553", "title": "Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus (SLE)" ], "interventions": [ { "name": "Anifrolumab", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oklahoma Medical Research Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 20, "start_date": "2021-01-20", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2023-03-22", "last_synced_at": "2026-09-26T18:50:34.631Z", "location_count": 5, "location_summary": "New Haven, Connecticut • Atlanta, Georgia • New York, New York + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT04726553" }, { "nct_id": "NCT00003239", "title": "Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Recombinant Interferon Alfa", "type": "BIOLOGICAL" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Omacetaxine Mepesuccinate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 90, "start_date": "1998-03", "completion_date": "2001-10", "has_results": false, "last_update_posted_date": "2012-07-30", "last_synced_at": "2026-09-26T18:50:34.631Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003239" }, { "nct_id": "NCT06582017", "title": "Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Pancreas Cancer", "Urothelial Carcinoma", "Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Gastrointestinal Cancer", "Lung Cancer", "Prostate Cancer", "Breast Cancer" ], "interventions": [ { "name": "QXL138AM Injection every 2 weeks by IV Infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nammi Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-08-28", "completion_date": "2028-05-30", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-26T18:50:34.631Z", "location_count": 10, "location_summary": "Los Angeles, California • Newport, California • Denver, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06582017" }, { "nct_id": "NCT03588715", "title": "Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV", "HIV/AIDS", "HIV-1 Infection" ], "interventions": [ { "name": "Pegylated Interferon alpha 2b (peg-IFN-α2b)", "type": "DRUG" }, { "name": "3BNC117 + 10-1074", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Luis Montaner", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2020-06-18", "completion_date": "2022-10-30", "has_results": false, "last_update_posted_date": "2021-06-25", "last_synced_at": "2026-09-26T18:50:34.631Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03588715" }, { "nct_id": "NCT00467077", "title": "Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "PEG-interferon alfa-2b", "type": "BIOLOGICAL" }, { "name": "gefitinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "California Cancer Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 21, "start_date": "2004-09", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2017-03-17", "last_synced_at": "2026-09-26T18:50:34.631Z", "location_count": 3, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00467077" }, { "nct_id": "NCT00207363", "title": "Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Ribavirin, Peg interferon alfa 2b", "type": "DRUG" }, { "name": "induction therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brooke Army Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 610, "start_date": "2002-02", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2012-02-14", "last_synced_at": "2026-09-26T18:50:34.631Z", "location_count": 1, "location_summary": "Fort Sam Houston, Texas", "locations": [ { "city": "Fort Sam Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00207363" }, { "nct_id": "NCT00485563", "title": "A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "EC90 (KLH-FITC)", "type": "BIOLOGICAL" }, { "name": "GPI-0100", "type": "BIOLOGICAL" }, { "name": "EC17 (Folate-FITC)", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Interferon-alpha", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Endocyte", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2007-06", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2012-03-08", "last_synced_at": "2026-09-26T18:50:34.631Z", "location_count": 3, "location_summary": "Omaha, Nebraska • Hackensack, New Jersey • Houston, Texas", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00485563" }, { "nct_id": "NCT01404936", "title": "Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Interferon-2A", "type": "DRUG" }, { "name": "Adriamycin", "type": "DRUG" }, { "name": "Bleomycin", "type": "DRUG" }, { "name": "Velban", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 35, "start_date": "1996-07", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2013-02-01", "last_synced_at": "2026-09-26T18:50:34.631Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01404936" }, { "nct_id": "NCT00002657", "title": "SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 20, "start_date": "1995-05", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-09-26T18:50:34.631Z", "location_count": 86, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002657" } ] }